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INTRODUCTION & OBJECTIVES: The trifecta outcome represents the primary target of nephron sparing surgery. Predictive factors of
trifecta achievement are still under evaluation. Few studies have analyzed the predictive role of nephrometric scores in this clinical field.
MATERIAL & METHODS: The data of 440 patients treated with open partial nephrectomy for T1 RCC were reviewed in our multi-center
prospectively maintained database. The perioperative clinical variables associated with the Trifecta outcome, defined as warm ischemia
time (WIT)perioperative complications, were assessed with univariate analysis. The variables independently associated with trifecta were
assessed with multivariate analysis.
RESULTS: The trifecta outcome was achieved in 315(71.6%) patients; 7.5% of patients had WIT≥25 min, 3.5% had PSM and 21.2% had
perioperative complications. Reoperation rate for Clavien≥3 complication was 6.7%. On univariate analysis the trifecta was significantly
associated with female gender(p<0.0001), lower clinical tumor size (p=0.03), no involvement of renal sinus (p=0.004), lower PADUA
(p=0.001), and R.E.N.A.L. score (p=0.003), elective/relative surgical indication (p=0.01), intraoperative estimated blood loss (EBL)<500 cc
(p<0.0001), and with Fuhrman grade 1-2(p=0.04). On the multivariate analysis the R.E.N.A.L. and PADUA score (analyzed separately) and
EBL (R=2.34, p=0.037)were confirmed as independent predictors of the trifecta outcome.
CONCLUSIONS: In our analysis the clarity of the surgical field, associated to the containment of intraoperative bleeding and a favorable
tumor nephrometry, resulted of critical importance for the achievement of excellent surgical outcome.
Patients   OPN Patients    with TRIFECTA
Patients  without  
Trifecta
Univariate  
analysis
Multivariate   
analysis
P   value R P 95%   C.I.
N   (%) 315   (71.6%) 125   (28.4%)     
Age   at surgery 63.4   ± 12.9 64.3   ±12.9 0.74 - - -
Male   gender 193   (61.3%) 88   (70.4%) <0.0001 0.78 0.33 0.48   –1.28
BMI 26.0 (23.6-28.0) 26 (23.3-28.9) 0.49    
Clinical tumor size 3.4 ± 1.6 3.8 ± 1.8 0.03 0.951 0.50 0.82 –1.10
Polar location 178 (56.5%) 58 (46.4%) 0.06 - - -
Prevalent exophytic growth pattern 151 (47.9%) 49 (39.2%) 0.07 - - -
Medial   rim location 61   (19.4%) 22   (17.6%) 0.26 - - -
Involvement   of renal sinus 56   (17.8%) 38   (30.4%) 0.004 0.882 0.74 0.42   –1.85
UCS   dislocated/infiltrated 59  (18.7%) 38 (30.4%) 0.015 - - -
PADUA  score* 7   (7-8) 8   (7-9) 0.001 1.34 0.009* 1.08   –1.69
R.E.N.A.L.  score* 5   (5-6) 6   (5-7) 0.003 1.43 0.012* 1.09   –1.72
Preop.   Blood Hemoglobin 14.0   ± 1.4 13.8   ± 1.5 0.13 - - -
Preop.   Serum Creatinine 0.9   ± 0.3 1.1   ± 0.5 0.21 - - -
Imperative  indication 22   (7.0%) 18   (14.4%) 0.001 1.877 0.122 0.84   –4.17
Operative   time 111.7   ± 32.6 127.8  ± 44.1 0.001 - - -
Pedicle   clamping 237   (75.2%) 91   (72.8%) 0.25 - - -
Warm   ischemia time 16.0   ± 4.0 21.3  ± 9.0 <0.0001 - - -
EBL ≥ 500
EBL (cc)      mean ± SD
17   (5.4%)
180.4   ± 143.3
19  (15.2%)
275.1   ± 204.1 <0.0001 2.34 0.037
1.05   –
5.18
Lenght   of Stay 6   (5-7) 6   (6-7) 0.006 - - -
Postoperative   complications (any
Clavien) 0 94   (75.2%) - - - -
Clavien   ≥ 3 complications 0 29   (23.2%) - - - -
Benign   tumors 53/315   (16.8%) 21/125   (16.8%) 0.53 - - -
Positive   surgical margins 0 13/104   (12.5%) - - - -
Fuhrman   grade 3-4 33/262   (10.5%) 23/104   (18.4%) 0.04 0.951 0.50 0.82 –1.10
Perirenal   fat invasion 13/262   (5.0%) 9/104   (7.2%) 0.139 - - -
